Skip to main content

Table 3 Uni- and multivariate analyses to identify predictors of recurrence-free and overall survival of patients with hepatocellular carcinoma after hepatectomy

From: Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy

Variable

Recurrence-free survival

Overall survival

Univariate analysis

P

Multivariate analysis

P

Univariate analysis

P

Multivariate analysis

P

Sex (female)

0.861 (0.666–1.113)

0.253

  

0.758 (0.540–1.065)

0.110

  

Age (>60 years)

0.876 (0.695–1.105)

0.263

  

0.976 (0.730–1.304)

0.868

  

Tumor size (>5 cm)

1.822 (1.483–2.238)

<0.001

1.303 (1.038–1.635)

0.022

2.537 (1.902–3.385)

<0.001

1.409 (1.027–1.934)

0.034

Number of tumors (multiple)

1.491 (1.236–1.797)

<0.001

1.421 (1.175–1.718)

<0.001

1.532 (1.215–1.932)

<0.001

1.509 (1.192–1.923)

0.001

Tumor capsule (incomplete)

1.556 (1.267–1.910)

<0.001

1.292 (1.044–1.599)

0.019

1.927 (1.510–2.459)

<0.001

1.518 (1.174–1.961)

0.001

MVI (positive)

1.622 (1.349–1.950)

<0.001

1.333 (1.095–1.623)

0.004

2.173 (1.701–2.774)

<0.001

1.589 (1.222–2.066)

0.001

BCLC stage (C)

2.209 (1.840–2.651)

<0.001

1.680 (1.309–2.155)

<0.001

3.452 (2.755–4.326)

<0.001

2.239 (1.651–3.036)

<0.001

Edmonson grade (III–IV)

1.841 (1.467–2.311)

<0.001

0.954 (0.720–1.264)

0.741

2.727 (2.100–3.540)

<0.001

1.003 (0.727–1.384)

0.985

HbsAg (positive)

1.217 (0.928–1.594)

0.155

  

0.933 (0.675–1.287)

0.671

  

Liver cirrhosis (yes)

1.066 (0.890–1.277)

0.486

  

1.009 (0.802–1.268)

0.942

  

Child–Pugh score (B)

1.256 (0.708–2.227)

0.436

  

1.893 (1.037–3.456)

0.038

1.174 (0.624–2.208)

0.618

Serum albumin (>35 g/L)

0.850 (0.649–1.112)

0.236

  

0.598 (0.440–0.812)

0.001

0.841 (0.606–1.168)

0.301

ALT (>40 U/L)

1.266 (1.055–1.519)

0.011

0.977 (0.785–1.216)

0.837

1.360 (1.084–1.707)

0.008

0.963 (0.740–1.259)

0.781

AST (>40 U/L)

1.595 (1.334–1.906)

<0.001

1.233 (0.990–1.537)

0.061

2.019 (1.610–2.532)

<0.001

1.405 (1.075–1.838)

0.013

TBil (>17.1 μmol/mL)

0.889 (0.709–1.114)

0.306

  

0.965 (0.728–1.280)

0.804

  

AFP (>400 ng/mL)

1.267 (1.061–1.514)

0.009

1.051 (0.850–1.300)

0.644

1.558 (1.245–1.951)

<0.001

1.308 (0.995–1.720)

0.054

CA19-9 (>37 U/mL)

1.463 (1.193–1.794)

<0.001

1.393 (1.038–1.870)

0.027

1.665 (1.301–2.132)

<0.001

1.717 (1.188–2.483)

0.004

Tumor marker type (double positive)

1.608 (1.229–2.104)

0.001

1.027 (0.683–1.546)

0.895

1.875 (1.362–2.581)

<0.001

1.259 (0.763–2.791)

0.366

  1. MVI microvascular invasion, BCLC Barcelona Clinic Liver Cancer Staging System, HBsAg hepatitis B surface antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, TBil total bilirubin, AFP α-fetoprotein, CA19-9 carbohydrate antigen 19-9